Google News

New renal disease biotech R1 Therapeutics nabs $77.5M for Phase 2b  Endpoints NewsR1 zooms out of stealth with $77.5M series A to advance chronic kidney disease treatment  Fierce BiotechR1 starts up with $78M, aiming for a better kidney drug  BioPharma DiveBiotechnology Start-Up Partners with Alebund Pharmaceuticals to Develop New Therapy for Hyperphosphatemia in CKD Patients  geneonline.comAlebund Pharmaceuticals Announces Collaboration and License Agreement with R1 Therapeutics for AP306  Yahoo Finance